Metal Abstraction Peptide (MAP) Tag and Associated Methods
Compositions comprising a tripeptide having the sequence XC 1 C 2 ; wherein X is any amino acid such that XC 1 C 2 is capable of binding a metal in a square planar orientation or square pyramidal orientation or both; and wherein C 1 and C 2 are the same or different; and wherein C 1 and C 2 individually are chosen from a cysteine and a cysteine-like nonnatural amino acid, as well as metal-XC 1 C 2 complexes and methods for forming such complexes.
1 - 20 . (canceled)
21 . A complex comprising:
a) an antibody; and
b) a hydrophilic group with a non-zero electric charge covalently bound to the antibody,
wherein the complex is more soluble in water than is the antibody alone.
22 . The complex of claim 21 , wherein the hydrophilic group is bound to the antibody by an amide bond.
23 . The complex of claim 21 , wherein the electric charge is a negative charge.
24 . The complex of claim 21 , wherein the complex is isolated.
25 . The complex of claim 21 , wherein the complex is synthetic.
26 . The complex of claim 21 , wherein the hydrophilic group is poorly soluble in an organic solvent.
27 . The complex of claim 21 , wherein the complex is more soluble at basic pH than at acidic pH.
28 . The complex of claim 21 , wherein the complex has a density that is greater than the density of the antibody alone.
29 . The complex of claim 21 , wherein the hydrophilic group is fluorescent.
30 . The complex of claim 21 , wherein the hydrophilic group has a molecular mass that is less than 400 Daltons.
31 . The complex of claim 21 , wherein the hydrophilic group has a molecular mass that is less than 340 Daltons.
32 . The complex of claim 21 , wherein the complex has lower toxicity than does the antibody alone.
33 . The complex of claim 21 , wherein the complex has a therapeutic application, wherein the complex is effective in the therapeutic application at a lower concentration than is the antibody alone.
34 . The complex of claim 21 , wherein the complex further comprises a metal.
35 . The complex of claim 34 , wherein the complex binds the metal at basic pH.
36 . The complex of claim 34 , wherein the complex releases the metal at acidic pH.
37 . The complex of claim 34 , wherein the hydrophilic group binds the metal.
38 . The complex of claim 34 , wherein the complex binds the metal in a square geometry.
39 . The complex of claim 38 , wherein the square geometry is square planar or square pyramidal.
40 . The complex of claim 34 , wherein the metal is a radioisotope.
41 . The complex of claim 34 , wherein the metal is zinc.
42 . The complex of claim 34 , wherein the metal is platinum.
43 . The complex of claim 34 , wherein the metal is nickel.
44 . The complex of claim 34 , wherein the metal is copper.
45 . The complex of claim 34 , wherein the metal is 62 Cu.
46 . The complex of claim 21 , wherein the hydrophilic group comprises an amino acid sequence.
47 . The complex of claim 46 , wherein the amino acid sequence comprises XC 1 C 2 , wherein X is any natural or unnatural amino acid or analogue thereof; and C 1 and C 2 are each independently a sulfur-containing amino acid.
48 . The complex of claim 47 , wherein X is a basic amino acid.
49 . The complex of claim 47 , wherein X is asparagine.
50 . The complex of claim 47 , wherein X is histidine.
51 . The complex of claim 47 , wherein at least one of C 1 and C 2 is cysteine.
52 . The complex of claim 47 , wherein both C 1 and C 2 are cysteine.